This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, A. Y.Y. Articles by Julian, J. A. Search for Related Content PubMed PubMed Citation Articles by Lee, A. Y.Y. Articles by Julian, J. A. Social Bookmarking                            What's this?

Incidence, Risk Factors, and Outcomes of Catheter-Related Thrombosis in Adult Patients With Cancer

Agnes Y.Y. Lee, Mark N. Levine, Gregory Butler, Carolyn Webb, Lorrie Costantini, Chushu Gu, Jim A. Julian

From the Departments of Medicine, Clinical Epidemiology & Biostatistics, and Radiology, McMaster University; and the Henderson Research Centre; and the Hamilton Health Sciences, Hamilton, Ontario, Canada

Address reprint requests to Agnes Y.Y. Lee, MD, Hamilton Health Sciences Henderson Hospital, 711 Concession St, Hamilton, ON L8V 1C3 Canada; e-mail: alee{at}mcmaster.ca

PURPOSE: Thrombosis of long-term central venous catheters (CVC) is a serious complication that causes morbidity and interrupts the infusion of chemotherapy, intravenous medication, and blood products. We performed a prospective study to examine the incidence, risk factors, and long-term complications of symptomatic catheter-related thrombosis (CRT) in adults with cancer.

PATIENTS AND METHODS: Consecutive patients with cancer, undergoing insertion of a CVC, were enrolled and prospectively followed while their catheter remained in place plus 4 subsequent weeks or a maximum of 52 weeks, whichever came first. Patients with symptomatic CRT were followed for an additional 52 weeks from the date of CRT diagnosis. The end points were symptomatic CRT, symptomatic pulmonary embolism (PE), postphlebitic syndrome, and catheter life span.

RESULTS: Over 76,713 patient-days of follow-up, 19 of 444 patients (4.3%) had symptomatic CRT in 19 of 500 catheters (0.3 per 1,000 catheter-days). The median time to CRT was 30 days and the median catheter life span was 88 days. Significant baseline risk factors for CRT were: more than one insertion attempt (odds ratio [OR] = 5.5; 95% CI, 1.2 to 24.6; P = .03); ovarian cancer (OR = 4.8; 95% CI, 1.5 to 15.1; P = .01); and previous CVC insertion (OR = 3.8; 95% CI, 1.4 to 10.4; P = .01). Nine of the 19 CRT patients were treated with anticoagulants alone, eight patients were treated with anticoagulants and catheter removal, while two patients did not receive anticoagulation. None had recurrent CRT or symptomatic PE. Postphlebitic symptoms were infrequent.

CONCLUSION: In adults with cancer, the incidence of symptomatic CRT is low and long-term complications are uncommon.

Supported by the Hamilton Regional Cancer Centre Foundation, Juravinski Cancer Centre, Hamilton, Ontario, Canada.

Presented in part at the American Society of Hematology Annual Meeting, San Diego, CA, December 4-7, 2004.

Agnes Y.Y. Lee, MD, is a recipient of a New Investigator Award from the Canadian Institutes of Health Research Research and Development Program.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. A. Khorana, M. B. Streiff, D. Farge, M. Mandala, P. Debourdeau, F. Cajfinger, M. Marty, A. Falanga, and G. H. Lyman Venous Thromboembolism Prophylaxis and Treatment in Cancer: A Consensus Statement of Major Guidelines Panels and Call to Action J. Clin. Oncol., October 10, 2009; 27(29): 4919 - 4926. [Abstract] [Full Text] [PDF]

				A. A. Khorana and G. C. Connolly Assessing Risk of Venous Thromboembolism in the Patient With Cancer J. Clin. Oncol., October 10, 2009; 27(29): 4839 - 4847. [Abstract] [Full Text] [PDF]

				S. P. Shivakumar, D. R. Anderson, and S. Couban Catheter-Associated Thrombosis in Patients With Malignancy J. Clin. Oncol., October 10, 2009; 27(29): 4858 - 4864. [Abstract] [Full Text] [PDF]

				P. Debourdeau, D. Kassab Chahmi, G. Le Gal, I. Kriegel, E. Desruennes, M.-C. Douard, I. Elalamy, G. Meyer, P. Mismetti, M. Pavic, et al. 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group Ann. Onc., September 1, 2009; 20(9): 1459 - 1471. [Abstract] [Full Text] [PDF]

				M. De Cicco, M. Matovic, L. Balestreri, A. Steffan, R. Pacenzia, M. Malafronte, D. Fantin, C. A. Bertuzzi, F. Fabiani, S. Morassut, et al. Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies Ann. Onc., June 30, 2009; (2009) mdp235v1. [Abstract] [Full Text] [PDF]

				S. Cesaro, G. Tridello, M. Cavaliere, L. Magagna, P. Gavin, R. Cusinato, N. Zadra, G. Franco Zanon, L. Zanesco, and M. Carli Prospective, Randomized Trial of Two Different Modalities of Flushing Central Venous Catheters in Pediatric Patients With Cancer J. Clin. Oncol., April 20, 2009; 27(12): 2059 - 2065. [Abstract] [Full Text] [PDF]

				T. Sousou and A. A. Khorana New Insights Into Cancer-Associated Thrombosis Arterioscler Thromb Vasc Biol, March 1, 2009; 29(3): 316 - 320. [Abstract] [Full Text] [PDF]

				W. H. Geerts, D. Bergqvist, G. F. Pineo, J. A. Heit, C. M. Samama, M. R. Lassen, and C. W. Colwell Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 381S - 453S. [Abstract] [Full Text] [PDF]

				R. S. Boersma, K.-S. G. Jie, A. Verbon, E. C. M. van Pampus, and H. C. Schouten Thrombotic and infectious complications of central venous catheters in patients with hematological malignancies Ann. Onc., March 1, 2008; 19(3): 433 - 442. [Abstract] [Full Text] [PDF]

				F. J. Munoz, P. Mismetti, R. Poggio, R. Valle, M. Barron, M. Guil, M. Monreal, and for the RIETE Investigators Clinical Outcome of Patients With Upper-Extremity Deep Vein Thrombosis: Results From the RIETE Registry,{dagger} Chest, January 1, 2008; 133(1): 143 - 148. [Abstract] [Full Text] [PDF]

				G. H. Lyman, A. A. Khorana, A. Falanga, D. Clarke-Pearson, C. Flowers, M. Jahanzeb, A. Kakkar, N. M. Kuderer, M. N. Levine, H. Liebman, et al. American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer J. Clin. Oncol., December 1, 2007; 25(34): 5490 - 5505. [Abstract] [Full Text] [PDF]

				D Fagnani, R Franchi, C Porta, P Pugliese, K Borgonovo, A Bertolini, M Duro, A Ardizzoia, V Filipazzi, L Isa, et al. Thrombosis-related complications and mortality in cancer patients with central venous devices: an observational study on the effect of antithrombotic prophylaxis Ann. Onc., March 1, 2007; 18(3): 551 - 555. [Abstract] [Full Text] [PDF]